CAMBRIDGE — A month after shelving plans for an initial public offering because of what it called volatile market conditions, Radius Health Inc. is weighing other ways to raise the roughly $55 million needed to take its experimental osteoporosis drug through the next stage of development.

While the nine-year-old biotech still may seek to go public, chief executive Michael S. Wyzga said he also has begun talking to private investors about a new round of financing and is considering selling part of the company to a larger firm.